The reporter learned from the China Automotive Technology and Research Center yesterday that China’s new vehicle collision assessment protocol C-NCAP plans to increase the requirements on an existing basis and will launch the 2012 version of the rules in the second half of this year. The new rules will reduce the average vehicle score by 3 points. Further improve the vehicle safety evaluation standards, especially to improve the five-star standard threshold.
According to Liu Yuguang, deputy chief engineer of the new version of Collision Speed, the new version of the rules not only increases the collision speed of the vehicle, but also increases the evaluation of vehicle rear-end safety, active safety systems such as ESP, and pedestrian safety. Among them, the new version of the rule will increase the speed of offset collision from 56km/h to 64km/h, and increase the quantitative evaluation of the head and chest in the female dummy of the back row.
In addition, the new version of the C-NCAP rule will also add two additional tests based on the basic test—the whipping test and the pedestrian protection test. According to reports, the whiplash test is designed to examine the safety performance of the vehicle after the rear-end collision, such as the ability of the front seat and headrest to protect the cervical spine of the occupants.
Liu Yuguang stated that the scope of C-NCAP's current investigation is limited to passive safety, that is, when a collision cannot be avoided. After the revision, C-NCAP will move closer to "integrated security" to examine the vehicle's active safety system, vehicle rear-end safety, and pedestrian protection. However, tests on the safety of the vehicle roof when consumers are concerned about the rolling of the vehicle have not yet been involved. The reporter learned that although the basic experimental project of C-NCAP after the revision was still 100% positive collision, 40% positive offset collision and side collision.
The number of five-star vehicles is expected to decrease. Zhao Hang, director of the China Automotive Technology and Research Center, told reporters that the more direct performance after the standard increase is that C-NCAP will no longer have an excessive number of five-star and four-star vehicles to help consumers to select superior vehicles. excellent. Liu Yuguang said that in accordance with the current revision plan, if future collision vehicles want five-star evaluation, electronic stability control systems, brake assist systems, vehicle speed limiting devices, tire pressure monitoring systems, adaptive lighting systems, and vehicle collision avoidance must be installed. Two of the system's four-star evaluation results must also be obtained with at least one of the above systems.
Zhao Hang believes that the excessive number of five-star vehicles proves that the safety performance is improved, but also shows that the promotion effect of C-NCAP on consumers' purchase of cars is relatively weakened. The more stringent revision of the safety collision standard is also synchronized with the European NCAP. It is reported that for the first time this year, European NCAP has incorporated advanced driver assistance technologies such as electronic stability control and prevention of neck sprains into the evaluation system.
Will increase enterprise costs "The increase in standards will inevitably drive auto companies to improve product safety standards and quality." Well-known automotive marketing communications experts and automotive industry commentator Zhang Zhiyong (microblogging) said in an interview with reporters that car prices on the safety performance of the car It is an inevitable trend in the future, but it will also increase the cost of the company and reduce the profit margin.
It is understood that C-NCAP is an abbreviation of China's automobile collision assessment procedures. C-NCAP organizer China Automotive Technology and Research Center is a technical organization authorized by the government to formulate Chinese automobile standards and regulations and participate in international coordination. The reporter was informed that since the implementation of C-NCAP five years ago, there have been 118 models in China that have participated in safety collision assessment.
Question C-NCAP had been questioned by CCTV In June 2008, CCTV's “Half an Hour in Economy†column reported on the domestic C-NCAP crash test and questioned the collision standard setting. The problems are mainly concentrated on two aspects. First, the test standards are formulated by C-NCAP itself, and the test standards in Europe and Japan are jointly formulated by the state, industry associations, and consumers. Second, manufacturers of vehicles under test can participate in tests. Tests by foreign test organizations are completely out of reach of automobile manufacturers. Testing costs are funded by organizations or by government funds.
It is understood that the five-star vehicles were scarce when the crash test was implemented, and then there was a surge. In last year's 30 collision models, the proportion of vehicles with more than five stars was 50%.
Responding to 70% of collision vehicles is self-selected. It was learned last month that experts and related technicians from C-NCAP Management Center, domestic vehicle manufacturers, some multinational companies or their R&D institutions in China, and some parts and components manufacturers. Participated in the "2012 version of the management rules exchange seminar", the development of the new rules is said to have been fully discussed within the industry.
Regarding the auto companies' participation in testing, the China Automotive Technology and Research Center told reporters that from last year's data, 70% of the vehicles involved in the crash test were purchased randomly by C-NCAP in the market, and only 30% of the crash test vehicles were involved. It is a business application.
Baricitinib API
Baricitinib is an orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), with potential anti-inflammatory, immunomodulating and antineoplastic activities. Upon administration, baricitinib binds to JAK1/2, which inhibits JAK1/2 activation and leads to the inhibition of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This decreases the production of inflammatory cytokines and may prevent an inflammatory response. In addition, baricitinib may induce apoptosis and reduce proliferation of JAK1/2-expressing tumor cells. JAK kinases are intracellular enzymes involved in cytokine signaling, inflammation, immune function and hematopoiesis; they are also upregulated and/or mutated in various tumor cell types.
Baricitinib is an orally available small molecule inhibitor of Janus kinases that is used to treat moderate-to-severe rheumatoid arthritis and more recently was given emergency use authorization as therapy in combination with remdesivir for severe COVID-19. Baricitinib is associated with transient and usually mild elevations in serum aminotransferase levels during therapy but has yet to be linked to cases of clinically apparent acute liver injury.
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators. Rheumatoid arthritis is a progressive autoimmune disease commonly associated with discomfort, diasability, and joint damage. Throughout disease progression, the disease may further lead to joint erosions and deformities, causing premature mortality, functional impairment, and reduced quality of life. While there are several disease modifying antirheumatic drugs (DMARDs) available for treatment, patients often experience inadequate threapeutic resposes to these drugs. In animal models of inflammatory arthritis, baricitinib was shown to have significant anti-inflammatory effects, but also led to preservation of cartilage and bone, with no detectable suppression of humoral immunity or adverse hematologic effects. In the EU, baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate. It is marketed under the trade name Olumiant. Baricitinib in combination with [remdesivir] for the treatment of COVID-19, was granted an FDA Emergency Use Authorization on 19 November 2020.
Baricitinib; 1187594-09-7; INCB028050; LY3009104; 2-(3-(4-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-1H-Pyrazol-1-Yl)-1-(Ethylsulfonyl)Azetidin-3-Yl)Acetonitrile; INCB 028050;
 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com